Niemann-Pick Type C1 - Articles and news items

Vtesse appoints Jason Meyenburg as Chief Commercial Officer

Industry news / 4 January 2017 / Niamh Louise Marriott, Digital Editor

Meyenburg joins the company from Alexion Pharmaceuticals, where he most recently served as Senior Vice President of Commercial Operations.

UK regulatory support for Vtesse’s Niemann-Pick drug for children

Industry news / 4 November 2016 / Niamh Louise Marriott, Digital Content Producer

The MHRA has granted a Promising Innovative Medicine designation for VTS-270, Vtesse’s investigational drug for children with Niemann-Pick Type C1 disease…

neimann

Vtesse doses first patient in Phase 2b/3 Niemann-Pick Type C1 trial

Industry news / 7 October 2016 / Niamh Louise Marriott, Digital Content Producer

The VTS-270 clinical program is aimed at treating the neurological disease that is the primary cause of child mortality with Niemann-Pick Type C1 disease…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+